1. Drug type: Fusion protein
2. Indications: Advanced solid tumors, especially those with high expression of CD155, Hepatocellular carcinoma, prostate cancer, colorectal cancer, gastric adenocarcinoma, endometrial cancer and so on.
3. Research progress:
a) The proof of concept that TIGIT-Fc can promote anti-tumor immunity was completed;
b) The tumor activity of TIGIT-Fc antibody was preliminarily verified in the tumor mouse model of CT26 and MC38;
c) In CT26 and MC38 tumor mouse models, it was preliminarily verified that the combination of TIGIT-Fc and anti-PD-L1 can improve the anti-tumor efficacy.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.